Ameritas Advisory Services’s iShares US Pharmaceuticals ETF IHE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$292K Buy
2,905
+334
+13% +$34.3K 0.01% 957
2026
Q2
$255K Buy
+2,571
New +$232K 0.01% 1007
2025
Q4
– Sell
-1,220
Closed -$88.5K – 1505
2025
Q3
$88.5K Sell
1,220
-1,354
-53% -$93.4K 0.01% 883
2025
Q2
$169K Buy
+2,574
New +$168K 0.01% 795
2023
Q2
– Sell
-1,155
Closed -$67.7K – 1516
2023
Q1
$67.7K Buy
+1,155
New +$69.6K ﹤0.01% 1146

Other funds holding IHE

Ameritas Advisory Services's IHE Position: Q3 2026 in Review

Ameritas Advisory Services increased its iShares US Pharmaceuticals ETF (IHE) stake by 13% in Q3 2026, buying an estimated $34.3K and bringing the position to 2,905 shares worth $292K. The position accounts for 0.01% of the portfolio, ranked #957.

Ameritas Advisory Services first reported a position in IHE in Q1 2023 and has held it in 5 quarters since. 249 funds tracked by Wall St. Rank hold IHE as of Q3 2026.

  • Ameritas Advisory Services held 2,905 shares of iShares US Pharmaceuticals ETF worth $292K as of Q3 2026.
  • Ameritas Advisory Services bought 334 iShares US Pharmaceuticals ETF shares in Q3 2026, an estimated $34.3K.
  • iShares US Pharmaceuticals ETF made up 0.01% of Ameritas Advisory Services's portfolio in Q3 2026, its #957 holding.
  • Ameritas Advisory Services first reported a position in iShares US Pharmaceuticals ETF in Q1 2023 and has held it in 5 quarters since.
  • 249 funds tracked by Wall St. Rank held iShares US Pharmaceuticals ETF as of Q3 2026.

Based on Ameritas Advisory Services's 13F filing for Q3 2026, filed 12 Nov 2026.